Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | JMJD6 | Q6NYC1 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.31 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27668438 | 0.98 | NLRP3 (0.40) | NLRP3KMT2AKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL2606651 | 0.80 | KMT2A (0.39) | NLRP3KMT2AKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL12000925 | 0.78 | NLRP3 (0.47) | NLRP3KMT2AKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL31442338 | 0.75 | KEAP1 (0.37) | NLRP3KMT2AKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL22871837 | 0.75 | L3MBTL1 (0.38) | NLRP3KMT2AKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL22942881 | 0.75 | KMT2A (0.41) | NLRP3KMT2AKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL19020095 | 0.74 | ALDH1A1 (0.40) | KMT2AKDM4ESMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL26115831 | 0.74 | NLRP3 (0.53) | NLRP3KMT2AKDM4ESMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28262904 | 0.72 | NLRP3 (0.43) | NLRP3KDM4EPOLBAPEX1TDP1 | |
| SCHEMBL15194196 | 0.71 | NR5A2 (0.35) | KDM4EPOLBAPEX1TDP1HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2438044-B1 | COMPOUNDS | JAPAN TOBACCO INC (JP) | 2019-01-23 | — | — | EP | claimed |
| EP-2438055-B1 | DIHYDROINDOLE AND TETRAHYDROISOQUINOLINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS | JAPAN TOBACCO INC (JP) | 2018-10-24 | — | — | EP | claimed |
| EP-2344456-B1 | NOVEL POTASSIUM CHANNEL BLOCKER | JAPAN TOBACCO INC (JP) | 2018-07-25 | — | — | EP | claimed |
| EP-2462117-B1 | QUINOLINYLOXYPHENYLSULFONAMIDES | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS E V (DE) | 2017-06-28 | — | — | EP | claimed |
| EP-2739614-B1 | AMINOCHROMANEs, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND (DE) | 2017-02-22 | — | — | EP | claimed |
| EP-2342177-B1 | NOVEL POTASSIUM CHANNEL BLOCKERS | JAPAN TOBACCO INC (JP) | 2017-02-15 | — | — | EP | claimed |
| EP-2334637-B1 | NOVEL POTASSIUM CHANNEL BLOCKERS | JAPAN TOBACCO INC (JP) | 2017-01-04 | — | — | EP | claimed |
| EP-2630129-B1 | QUINOXALINE DERIVATES | MERCK PATENT GMBH (DE) | 2016-10-26 | — | — | EP | claimed |
| US-9169241-B2 | Quinolinyloxyphenylsulfonamides | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2015-10-27 | — | — | US | claimed |
| US-9073834-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2015-07-07 | — | — | US | claimed |
| EP-2334637-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS | Xention Limited (GB) | 2011-06-22 | — | — | EP | claimed |
| WO-2010139967-A1 | DIHYDROINDOLE AND TETRAHYDROISOQUINOLINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS | XENTION LIMITED (GB) | 2010-12-09 | — | — | WO | claimed |
| WO-2010139953-A1 | COMPOUNDS | XENTION LIMITED (GB) | 2010-12-09 | — | — | WO | claimed |
| US-20100087428-A1 | Novel Potassium Channel Blockers | XENTION LIMITED (GB) | 2010-04-08 | — | — | US | claimed |
| US-20100087437-A1 | Novel Potassium Channel Blockers | XENTION LIMITED (GB) | 2010-04-08 | — | — | US | claimed |
| US-20100087438-A1 | New Potassium Channel Blockers | XENTION LIMITED (GB) | 2010-04-08 | — | — | US | claimed |
| WO-2010023445-A1 | NOVEL POTASSIUM CHANNEL BLOCKER | XENTION LIMITED (GB) | 2010-03-04 | — | — | WO | claimed |
| WO-2010023446-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS | XENTION LIMITED (GB) | 2010-03-04 | — | — | WO | claimed |
| WO-2010023448-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS | XENTION LIMITED (GB) | 2010-03-04 | — | — | WO | claimed |
| WO-2008079903-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS KINASE MODULATORS | PLEXXIKON, INC. (US) | 2008-07-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087438-A1 | New Potassium Channel Blockers | KCNJ2, KCNB1, KCNJ11 | NLRP3 706/4885KMT2A 836/4885KDM4E 599/4885 |
| US-20100087428-A1 | Novel Potassium Channel Blockers | HCN4, SCN2B, KCNH2 | NLRP3 2700/4885KMT2A 1511/4885KDM4E 1379/4885 |
| US-20100087437-A1 | Novel Potassium Channel Blockers | KCNB1, KCNJ2, KCNJ11 | NLRP3 751/4885KMT2A 777/4885KDM4E 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.